Announcements, milestones, partnerships, and presentations from our team — straight from the labs and the floor.
Pre-validated synthetic promoters and drug-induced switches enable safer, more precise, and clinically translatable cell and gene therapies.
Advancing cell therapy with process intensification.
GeneFab has partnered with RegCell, a biotech company advancing regulatory T cell (Treg) therapies for autoimmune diseases, to bring their lead program into U.S. clinical trials.
Bringing over 25 years of biopharmaceutical industry experience, Vadim will oversee Quality Assurance and Quality Control teams at GeneFab.
For the treatment of relapsed or refractory hematologic malignancies including acute myeloid leukemia.
Two poster presentations at the 27th Annual Meeting, May 7–11, 2024 in Baltimore, MD.
GeneFab's cGMP facility in the San Francisco Bay Area has available capacity to support new customers with complex cell and gene therapy manufacturing.
For press inquiries or to be added to our distribution list, reach out — we'll keep you posted.
